Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug (Q28282479)

Histone deacetylases and cancer: causes and therapies

Europe PubMed Central

title

Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug (English)

0 references

2

Ronald Breslow

0 references

author name string

Paul A Marks

series ordinal

1

0 references

language of work or name

English

0 references

publication date

January 2007

0 references

published in

Nature Biotechnology

0 references

volume

25

0 references

issue

1

0 references

page(s)

84-90

0 references

cites work

1 reference

Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation

21 January 2018

1 reference

Histone deacetylase inhibitors: discovery and development as anticancer agents

21 January 2018

1 reference

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications

21 January 2018

1 reference

Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors

21 January 2018

1 reference

Rapid alteration of microRNA levels by histone deacetylase inhibition

21 January 2018

1 reference

Apoptotic and autophagic cell death induced by histone deacetylase inhibitors

21 January 2018

1 reference

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

21 January 2018

1 reference

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies

21 January 2018

1 reference

Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies

21 January 2018

1 reference

Histone deacetylase inhibitors

21 January 2018

1 reference

Histone deacetylase inhibitors and cancer: from cell biology to the clinic

21 January 2018

1 reference

Histone deacetylase inhibitors: latest developments, trends and prospects

21 January 2018

1 reference

Epigenetic therapy of cancer: past, present and future

21 January 2018

1 reference

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

21 January 2018

1 reference

Hemoglobin synthesis in murine virus-induced leukemic cells in vitro: stimulation of erythroid differentiation by dimethyl sulfoxide

21 January 2018

1 reference

Excess α Chain Synthesis Relative to β Chain Synthesis in Thalassaemia Major and Minor

21 January 2018

1 reference

Induction of erythroid differentiation in murine virus infected eythroleukemia cells by highly polar compounds

21 January 2018

1 reference

A new group of potent inducers of differentiation in murine erythroleukemia cells

21 January 2018

1 reference

Erythroleukemic Differentiation

21 January 2018

1 reference

Potent cytodifferentiating agents related to hexamethylenebisacetamide

21 January 2018

1 reference

Second generation hybrid polar compounds are potent inducers of transformed cell differentiation.

21 January 2018

1 reference

Histone deacetylase: a target for antiproliferative and antiprotozoal agents

21 January 2018

1 reference

A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.

21 January 2018

1 reference

Histone Deacetylase Inhibitors

21 January 2018

1 reference

Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors

21 January 2018

1 reference

Clinical development of histone deacetylase inhibitors as anticancer agents

21 January 2018

1 reference

Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?

21 January 2018

1 reference

Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells

21 January 2018

1 reference

Histone deacetylase inhibitors in programmed cell death and cancer therapy

21 January 2018

1 reference

Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors

21 January 2018

1 reference

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

21 January 2018

1 reference

The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin.

21 January 2018

1 reference

Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1

21 January 2018

1 reference

Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease

21 January 2018

1 reference

Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.

21 January 2018

1 reference

Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid

21 January 2018

1 reference